SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ARB IOT Group Ltd. is a holding company that engages in the provision of solutions for the integration of IoT systems and devices. It operates through the Internet of Things and Investment Holding and Others segments. The company was founded on March 1, 2022 and is headquartered in Singapore.

ARB IOT Group Ltd

ARBB is trending as traders discuss its low float and potential for a significant breakout, drawing comparisons to other low-float stocks. Community members highlight the possibility of a short squeeze and anticipation for news catalysts, driving speculation about a potential run to higher price levels. Traders are closely monitoring key price levels as potential triggers for further upward momentum.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences ($GLSI) is trending due to positive buzz surrounding its FLAMINGO-01 trial and anticipation of potential news. The community highlights a preliminary analysis showing a significant recurrence rate reduction, fueling excitement. Discussions also revolve around the high short borrow rate and potential for a short squeeze, with some expecting major announcements soon.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending amid speculation around potential cannabis rescheduling, driven by reports of executive action and Supreme Court involvement. Community members are weighing the potential impacts on the sector, discussing possible rallies and short squeezes while considering potential volatility and the long-term implications for cannabis businesses. The focus remains on upcoming announcements and their effects on market dynamics.

nLIGHT, Inc. engages in the provision of semiconductor and fiber lasers for aerospace and defense, industrial, and microfabrication applications. It operates through the Laser Products and Advanced Development segments. The Laser Products segment designs, manufactures, and sells a range of semiconductor lasers and fiber lasers that are typically integrated into laser systems or manufacturing tools built by customers. The Advanced Development segment focuses on research, design, and prototyping of next-generation laser technologies, leveraging expertise in laser technology, development, beam control, and advanced optics. The company was founded by Scott H. Keeney, Mark DeVito, and Jason Farmer in June 2000 and is headquartered in Camas, WA.

nLIGHT Inc

nLIGHT ($LASR) is trending as chatter around defense contracts and the "Golden Dome" project heats up. The community speculates about potential benefits from increased defense spending and upcoming contracts. Some are also discussing the potential for a short squeeze.

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

KYTX is trending as investors await Phase 2 trial results for KYV-101 in stiff person syndrome, expected imminently, with some speculating about positive news catalysts before year-end. Community chatter highlights the potential for a significant breakout, noting institutional backing and a potentially undervalued stock price relative to cash on hand. Some analysts have recently updated their rating for KYTX to Overweight.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin is trending as the community discusses the potential for a strategic transaction, fueled by the recent COO promotion and Barclays remaining as advisor.  Discussion is also focused on the upcoming earnings report and potential catalysts such as China NRDL inclusion.  Community members are analyzing the company's financial health, revenue potential, and patent landscape.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

ARM is trending as investors assess its potential in the AI sector following a recent partnership announcement; the community is actively discussing the implications of this collaboration and its impact on ARM's growth trajectory. Recent analyst ratings and price target adjustments are also fueling the conversation around the stock's valuation. However, some traders note that ARM's stock movement can be manipulated due to its low float, making it a risky play.

Argo Blockchain Plc operates as a blockchain technology company focused on large-scale mining of Bitcoin and other cryptocurrencies. It mines using purpose-built computers to solve cryptographic algorithms in the blockchain in exchange for rewards and fees denominated in the native token of that blockchain network. The company was founded in 2017 and is headquartered in London, the United Kingdom.

Argo Blockchain Plc - ADR

Argo Blockchain Plc

ARBK is trending due to a potential short squeeze amplified by its nano float and recent reverse stock split, attracting both bullish and bearish sentiments. Traders are actively discussing its high volatility, low price, and the possibility of a dead cat bounce, with some comparing it to other high-potential squeeze candidates. The broader context includes its restructuring to avoid insolvency, delisting from the London Stock Exchange, and correlation with Bitcoin's movements, all contributing to the intense community debate.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is trending amid discussions around a potential acquisition of cybersecurity firm Armis, with community members weighing the strategic implications of expanding its security offerings. Keybanc's recent underweight rating is also contributing to the conversation. Additionally, the stock's technical indicators, including RSI and moving averages, are being analyzed for potential trade opportunities.

Compass, Inc. engages in the provision of an online real estate platform. Its platform provides an integrated suite of software for customer relationship management, marketing, client service, operations and other critical functionality, as well as brokerage services and adjacent services. The company was founded by Ori Allon and Robert Reffkin in 2012 and is headquartered in New York, NY.

Compass Inc - Ordinary Shares - Class A

COMP is trending as investors discuss its potential for growth in the mid-tier and luxury real estate markets, particularly with global expansion and strategic acquisitions being key talking points. Bullish sentiment is emerging, with some anticipating a breakout above the $11 resistance level, although overbought conditions indicated by high RSI values and recent analyst rating changes warrant caution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Redmile Group LLC Sells 102,106 Shares of IDEAYA Biosciences, Inc. $IDYA

Redmile Group LLC reduced its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 19.1% during the 2nd quarter, according to its most recent disclosure with the Securities and...

IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma

IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal...

Stempoint Capital LP Purchases 98,886 Shares of IDEAYA Biosciences, Inc. $IDYA

Stempoint Capital LP grew its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 147.6% in the second quarter, according to the company in its most recent 13F filing with...

IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers

IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers IDEAYA Biosciences Announces IND Submission for IDE574, a...

Hsbc Holdings PLC Has $804,000 Stake in IDEAYA Biosciences, Inc. $IDYA

Hsbc Holdings PLC reduced its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 55.7% during the second quarter, according to the company in its most recent 13F filing with the...

JPMorgan Chase & Co. Purchases 115,827 Shares of IDEAYA Biosciences, Inc. $IDYA

JPMorgan Chase & Co. raised its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 35.0% during the second quarter, according to its most recent disclosure with the...

IDEAYA Biosciences (NASDAQ:IDYA) Reaches New 52-Week High - Here's Why

IDEAYA Biosciences (NASDAQ:IDYA) Sets New 52-Week High - What's Next...

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) have received an average rating of "Moderate Buy" from the seventeen ratings firms that are covering the company, MarketBeat.com...

IDEAYA Biosciences (NASDAQ:IDYA) Hits New 52-Week High - Time to Buy?

IDEAYA Biosciences (NASDAQ:IDYA) Reaches New 12-Month High - Should You Buy...

IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types

IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types IDEAYA Biosciences Announces IND Clearance for...

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. It focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

IDYA
Ideaya Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IDYA News

IDYAIdeaya Biosciences Inc